Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine

Flink, Hajo; Hansen, Bettina; Heathcote, E.; Feinman, S.; Simsek, HALİS; Karayalcin, Selim; Mach, Tomasz; Leemans, Wim; de Man, Robert; Verhey, Elke; Schalm, Solko; Janssen, Harry

doi:10.1111/j.1572-0241.2006.00812.x

Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine

Flink H. J., Hansen B. E., Heathcote E. J., Feinman S. V., Simsek H., Karayalcin S., ...Daha Fazla

AMERICAN JOURNAL OF GASTROENTEROLOGY, cilt.101, sa.11, ss.2523-2529, 2006 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 101 Sayı: 11
Basım Tarihi: 2006
Doi Numarası: 10.1111/j.1572-0241.2006.00812.x
Dergi Adı: AMERICAN JOURNAL OF GASTROENTEROLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.2523-2529
Hacettepe Üniversitesi Adresli: Evet

Özet

OBJECTIVES: Antiviral therapy leads to HBeAg seroconversion in 10-40% of the patients with HBeAg-positive chronic hepatitis B. Nonresponse may result in progression of liver disease and increased risk of hepatocellular carcinoma. As part of a global randomized controlled trial we investigated the efficacy (i.e., loss of HBeAg at the end of follow-up) of peginterferon alfa-2b (Peg-IFN alpha 2b) in patients who failed to respond to previous courses of standard interferon (IFN) or lamivudine.